Trial

NCT00642902

A Phase 2 Study of Atacicept in Subjects With Relapsing Multiple Sclerosis (ATAMS)
Phase IITERMINATEDSAFETYConfidence: MEDIUM
Sponsor
EMD Serono
Collaborators
Condition
Relapsing Multiple Sclerosis
Intervention
Atacicept
Why stopped
Sponsor voluntarily decided to terminate trial due to increased MS disease activity in atacicept arms as compared to placebo during a routine IDMC review.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2016-05-24